Enovis (NYSE:ENOV) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other research firms also recently weighed in on ENOV. BTIG Research decreased their price target on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, September 1st. UBS Group reiterated a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Canaccord Genuity Group cut their price objective on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Evercore set a $32.00 price objective on Enovis in a report on Monday, July 6th. Finally, Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

Enovis Trading Up 6.2%

Shares of NYSE:ENOV opened at $19.54 on Friday. The company’s 50-day moving average price is $25.25 and its two-hundred day moving average price is $24.10. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. Enovis has a one year low of $18.08 and a one year high of $34.28. The stock has a market capitalization of $1.13 billion, a PE ratio of -1.01 and a beta of 1.31.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts forecast that Enovis will post 3.15 EPS for the current fiscal year.

Insider Activity

In other Enovis news, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction dated Friday, September 4th. The shares were bought at an average cost of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Oliver Engert purchased 2,660 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was acquired at an average price of $18.80 per share, with a total value of $50,008.00. Following the completion of the transaction, the insider owned 63,898 shares of the company’s stock, valued at $1,201,282.40. This represents a 4.34% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 24,293 shares of company stock valued at $470,519 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its position in shares of Enovis by 5,590.5% during the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares during the period. Arax Advisory Partners acquired a new position in Enovis in the fourth quarter valued at about $29,000. Allworth Financial LP acquired a new position in Enovis in the second quarter valued at about $36,000. Integrated Wealth Concepts LLC bought a new stake in Enovis during the second quarter worth about $39,000. Finally, EverSource Wealth Advisors LLC lifted its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.